Alprostadil

證據等級: L5

預測適應症: 10 個

Alprostadil: From Ductus-Dependent Congenital Heart Disease to Aortic Malformation

One-Sentence Summary

Alprostadil (Prostaglandin E1, PGE1) is a synthetic prostanoid clinically established as the preoperative bridge therapy for neonates with ductus-dependent congenital heart disease, maintaining patency of the ductus arteriosus (PDA) to preserve systemic or pulmonary perfusion until surgical correction. The TxGNN model predicts it may be effective for Aortic Malformation, with 2 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in Taiwan (TFDA: 0 licenses); established clinical use: PDA maintenance in ductus-dependent congenital heart disease
Predicted New Indication	Aortic Malformation
TxGNN Prediction Score	99.98%
Evidence Level	L3
Market Status	Not marketed (Taiwan)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Alprostadil is the synthetic form of prostaglandin E1 (PGE1), acting primarily through EP4 receptors on the smooth muscle of the ductus arteriosus to drive vasodilation and prevent spontaneous ductal closure. Since its clinical introduction in the late 1970s, PGE1 infusion has become the undisputed standard of care for preoperative stabilization of neonates with ductus-dependent cardiac lesions — effectively maintaining circulation until definitive surgical repair can be undertaken.

Aortic malformations — including interrupted aortic arch, aortic coarctation, aortic atresia, and critical aortic stenosis — represent the quintessential category of ductus-dependent systemic circulation disorders. In these conditions, perfusion of the descending aorta and lower body depends entirely or substantially on right-to-left flow through the PDA. Without an open ductus, neonates rapidly deteriorate into cardiogenic shock. Alprostadil restores and sustains this critical pathway, providing the hemodynamic stability necessary for pre-surgical resuscitation, diagnostic workup, and transfer to a cardiac surgery center.

Beyond ductal patency, one RCT (PMID 19080093) directly demonstrates that Lipo-PGE1 significantly attenuates the systemic inflammatory response and lung injury following cardiopulmonary bypass (CPB) in pediatric congenital heart disease patients — an anti-inflammatory pathway operating through prostaglandin-mediated suppression of neutrophil activation. This dual mechanistic rationale (EP4-mediated ductal vasodilation + post-CPB organ protection) substantially strengthens the biological basis for TxGNN’s prediction, and is independently supported by a case report demonstrating PGE1 efficacy in coarctation even after spontaneous ductal closure (PMID 31010402), suggesting mechanisms beyond simple PDA dilation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04054115	Phase 1	Terminated	10	Evaluated acute effects of alprostadil on cerebral and pulmonary blood flow after bidirectional cavopulmonary connection (BCPC) in single-ventricle palliation; confirmed biological plausibility of PGE1 in complex CHD hemodynamics, but terminated early (n=10) — provides Phase 1 safety signal only, no efficacy conclusion
NCT02042092	N/A	Completed	39	Cross-sectional diagnostic comparison of Color Doppler Ultrasonography vs MR Angiography in systemic large vessel vasculitis; not a direct alprostadil treatment trial — limited relevance to repurposing hypothesis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19080093	2008	RCT	Zhonghua Yi Xue Za Zhi	Alprostadil (Lipo-PGE1) + ulinastatin significantly reduces post-CPB inflammatory cytokines and lung injury in pediatric CHD patients; highest-quality direct evidence
6763200	1982	Prospective Observational	Pharmacotherapy	Foundational report: PGE1 infusion dilates ductus, raises SaO₂, and improves systemic and pulmonary perfusion across multiple congenital cardiac malformations including aortic defects
26686446	2015	Review	Semin Thorac Cardiovasc Surg	PGE1 revolutionized interrupted aortic arch management; establishes multi-day preoperative PGE1 resuscitation followed by one-stage direct anastomosis as current standard
31010402	2020	Case Report + Review	World J Pediatr Congenit Heart Surg	PGE1 successfully managed aortic coarctation with closed ductus; suggests direct aortic wall relaxation as mechanism independent of ductal patency
25647388	2014	Clinical Practice Review	Cardiology in the Young	Comprehensive neonatal critical aortic stenosis management; PGE1 essential for stabilizing left ventricular wall stress and preserving coronary perfusion before intervention
32184038	2020	Retrospective Cohort	Asian J Surg	Staged surgical repair for interrupted aortic arch (n not specified); PGE1 bridge is integral to achieving preoperative stability in all cases
16368373	2006	Retrospective Cohort	Ann Thorac Surg	Outcomes after treatment of critical aortic stenosis in neonates; preoperative PGE1 protocol supports safe surgical timing
1926911	1991	Review	DICP Ann Pharmacotherapy	Recommends initiating PGE1 at the referring hospital before neonatal transport for all suspected ductus-dependent defects including aortic lesions; defines standard of care
7201134	1982	Case Series	Pediatric Cardiology	PGE1 infusion in 7 neonates with hypoplastic left ventricle and aortic atresia; transient metabolic and circulatory improvement demonstrated in 6 of 7 cases
30347623	2019	Review	J Neonatal Perinat Med	Describes feeding strategies and NEC risk in infants on PGE1 for duct-dependent CHD; documents clinical management complexity during prolonged alprostadil infusions

Market Information (Taiwan TFDA)

No regulatory approvals found in the Taiwan FDA (TFDA) database for Alprostadil. The drug has 0 registered licenses in Taiwan as of the data cutoff (June 2026).

Context note: Alprostadil is approved by the US FDA under trade names Prostin VR Pediatric® (IV, for PDA maintenance in neonates), Caverject®, and MUSE® (for erectile dysfunction). The absence from Taiwan TFDA records represents a local registration gap rather than a global lack of regulatory approval.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alprostadil has a deeply established, mechanistically coherent role in aortic malformation — specifically ductus-dependent systemic circulation disorders — supported by over four decades of published clinical experience, one directly relevant Phase 1 trial, and an RCT demonstrating post-CPB organ protection benefit. The L3 evidence level reflects the absence of a dedicated Phase 2/3 RCT for this specific diagnostic label; however, the mechanistic basis is so well-characterized that this largely reflects standard-of-care practice documented in the literature rather than a novel repurposing hypothesis requiring de-novo proof-of-concept.

To proceed, the following is needed:

Taiwan regulatory pathway: Identify compassionate-use, special import, or hospital-formulary approval mechanisms given zero TFDA registrations
Safety data completion: Retrieve complete warnings, contraindications, and drug interaction profile from the TFDA or US FDA package insert (MOA and warnings are currently data gaps)
Indication stratification: Define specific aortic malformation subtypes (interrupted aortic arch / coarctation / aortic atresia / critical aortic stenosis) for targeted evaluation, as PGE1 benefit and dosing protocol may differ across subtypes
Prospective validation design: Consider a registry-based prospective cohort study to formally capture hemodynamic endpoints (ductal patency rate, pre-surgical SaO₂, time-to-surgery, post-CPB inflammatory markers) in a Taiwan pediatric population
Post-CPB lung protection protocol: Evaluate whether the alprostadil + ulinastatin combination (PMID 19080093 RCT) can be formally adopted into the pediatric cardiac surgery pathway at local centers
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.